Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...
The decision to go all-in on the programme comes two years after BMS paid $80 million to take exclusive, worldwide opt-in rights to PRX005, and means that the big pharma will now be responsible ...
Representatives from 100A associates will respond to you via e-mail. By sending this message you agree to the T&C.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback